Transdermal Drug Delivery Devices Market Summary
- The transdermal drug delivery devices market was valued at USD 71,566.27 million in 2024, and projected to reach USD 121,798.76 million by 2032.
- The transdermal drug delivery devices market is expected to grow at a CAGR of 6.91% during the forecast period from 2025 to 2032.
- The growing prevalence of chronic conditions, coupled with the increasing adoption of third-generation transdermal drug delivery devices, is significantly boosting the global market for these devices.
Key Market Trends & Insights
- Among all regions, North America Transdermal Drug Delivery Devices market is estimated to hold the largest share of 45.39% in the global transdermal drug delivery devices market in 2024, growing at a CAGR of 5.91% during the forecast period from 2025 to 2032.
- The leading Transdermal Drug Delivery Devices companies working in the Transdermal Drug Delivery Devices Market include B Braun Meslungen AG, BestMedical, MINZE HEALTH, Santron Meditronic., Potent Medical, Laborie, MEDKONSULT medical technology s.r.o., The Prometheus Group®, HCItalia srl, DeltaMed, MEDICA S.P.A, Aymed Medical Technology, EV.SERVICE ITALIA, tic Medizintechnik GmbH & Co. KG, Creo Medical Ltd, Stericom Ltd., Amecath Medical Technologies, Cook, Well Lead Medical Co., Ltd, and others.
- According to recent data from the Centers for Disease Control and Prevention (2024), approximately 4.9% of adults were diagnosed with coronary heart disease in 2022.
Transdermal Drug Delivery Device Market Size & Forecast
- 2024 Market Size: USD 71,566.27 million
- 2032 Projected Market Size: USD 121,798.76 million
- CAGR (2025-2032): 6.91%
- North America: Largest market in 2025
Factors Contributing to the Rise in Growth of the Transdermal Drug Delivery Devices Market
- Rapid rise in chronic diseases - conditions that need long-term, steady medication (e.g., diabetes, cardiovascular, pain management) increase demand for convenient transdermal options.
- Technological advances - innovations like microneedles, nanocarriers, skin-penetration enhancers, and novel adhesives have expanded the range of drugs that can be delivered through the skin.
- Patient preference for non-invasive, at-home care - patches and wearables reduce injections and hospital visits, improving adherence and quality of life.
- Growth of “smart”/connected patches - integration of sensors and digital monitoring enables personalized dosing, adherence tracking, and remote care.
- Aging population - larger geriatric cohorts who often prefer simpler, less invasive administration support market uptake.
- Improved bioavailability & controlled release - transdermal systems can bypass first-pass metabolism and provide steady plasma levels, attractive for many therapeutics.
- More regulatory approvals & favorable reimbursement pathways - increasing approvals for transdermal formulations encourage manufacturer investment and commercialization.
- Expanded therapeutic areas - beyond pain and nicotine, developers are targeting hormones, cardiovascular drugs, vaccines, and biologics (especially with microneedle platforms).
- Lower overall care costs potential - fewer clinic visits and hospital stays for some therapies improve the value proposition for payers and providers.
- Strong industry R&D and partnerships - pharma–device collaborations and growing investor interest accelerate product pipelines and market entry.
Transdermal Drug Delivery Devices Market by Type (Drug-in-adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Transdermal Drug Delivery Devices Market by Application (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Disorders, and Others), Transdermal Drug Delivery Devices Market by End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Transdermal Drug Delivery Devices Market by Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of chronic conditions, increase in adoption of third-generation transdermal drug delivery devices, technological advancements observed in the device, and use of these devices from hormonal disorders to cardiovascular conditions and pain management across the globe.
The transdermal drug delivery devices market was valued at USD 71,566.27 million in 2024, growing at a CAGR of 6.91% during the forecast period from 2025 to 2032 to reach USD 121,798.76 million by 2032. The growing prevalence of chronic conditions, coupled with the increasing adoption of third-generation transdermal drug delivery devices, is significantly boosting the global market for these devices. Technological advancements have enhanced device efficiency, improving drug absorption and patient convenience. Their versatile application across hormonal disorders, cardiovascular conditions, and pain management further drives demand, offering a non-invasive, controlled, and patient-friendly alternative for drug delivery. Together, these factors contribute to the expanding use and development of transdermal drug delivery devices worldwide during the forecast period from 2025 to 2032.
What are the latest Transdermal Drug Delivery Devices Market Dynamics and Trends?
According to recent data provided by the British Heart Foundation (2024), globally, approximately 620 million people, or about 1 in 13 individuals, live with heart and circulatory diseases.
Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, the most commonly diagnosed worldwide, affects an estimated 200 million people globally. Approximately 110 million men and 80 million women are affected. Additionally, around 56 million women and 45 million men are stroke survivors. It is estimated that at least 13 million people worldwide live with congenital heart disease, with potentially millions more undiagnosed. As the prevalence of CVDs rises globally, particularly among aging populations and individuals with sedentary lifestyles, the need for convenient, long-term treatment solutions has intensified. Thus, transdermal drug delivery devices allow for controlled and consistent delivery of medications like antihypertensives, antianginal drugs, and anticoagulants, ensuring better therapeutic outcomes and improved patient compliance thereby boosting the overall market across the globe.
Additionally, as per the recent data provided by the World Health Organization (2024), epilepsy affects approximately 50 million people worldwide, making it one of the most prevalent neurological disorders globally. Thus, with the rising prevalence of neurological disorders, there is a growing demand for non-invasive and effective treatment methods. These transdermal drug delivery devices provide controlled and consistent delivery of medications, bypassing the gastrointestinal tract and reducing side effects often associated with oral or injectable therapies thereby boosting the market of transdermal drug delivery devices across the globe.
Additionally, the increase in strategic activities among the key Transdermal Drug Delivery Devices companies is further boosting the market of transdermal drug delivery devices across the globe. For instance, in January 2024, Starton Therapeutics announced the launch of STARSILON a novel proprietary transdermal patch delivery platform.
Thus, the factors mentioned above are expected to boost the overall market of transdermal drug delivery devices across the globe during the forecast period from 2025 to 2032.
However, disadvantages associated with transdermal drug delivery devices such as irritation at the site of application edema and increased product recalls may hinder the future market of transdermal drug delivery devices across the globe during the forecasted period.
|
Report Metrics |
Details |
|
Study Period |
2022 to 2032 |
|
Base Year |
2024 |
|
Forecast Period |
2025 to 2032 |
|
Transdermal Drug Delivery Devices Market Size (2024) |
USD 71,566.27 million |
|
Transdermal Drug Delivery Devices Market Size (2O32) |
USD 121,798.76 million |
|
CAGR |
6.91% |
|
Key Companies | Hisamitsu Pharmaceutical, Mylan, UCB SA, Novartis, GlaxoSmithKline, Boehringer Ingelheim, Johnson & Johnson, Endo International, Purdue Pharma, Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Acrux Limited, Lavipharm, Lead Chemicals Co. Inc., Luye Pharma Group and others. |
Transdermal Drug Delivery Devices Market Segment Analysis
Transdermal Drug Delivery Devices Market by Type (Drug-in-adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Application (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Disorders, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
The drug-in-adhesive patches category in the transdermal drug delivery devices market is estimated to dominate the Transdermal Drug Delivery Devices market with a Transdermal Drug Delivery Devices market share of 55.44% in 2024. This can be attributed to the various advantages and applications provided by these adhesive patches which will be responsible for driving the demand for transdermal drug delivery devices market during the given forecast period. Drug-in-adhesive transdermal patches are a type of drug delivery system designed to deliver drugs through the skin and into the bloodstream. These patches are designed to release the drug over time, providing a controlled and consistent therapeutic dosage. The adhesive layer adheres the patch to the skin and also helps to control the rate at which the drug is released. When the patch is applied to the skin, the drug gradually diffuses through the skin and into the bloodstream, providing a steady and controlled release of medication over time.
Drug-in-adhesive transdermal patches are easy to apply and do not require needles or invasive procedures, making them more convenient and patient-friendly. These drug delivery systems provide a controlled and consistent release of medication over a prolonged period, which helps to maintain stable drug levels in the bloodstream. Further presence of some key Transdermal Drug Delivery Devices products in the market such as TRANSDERM-V by Novartis and Mylan-rivastigmine Patch 10 by Viatris Inc. will also contribute in propelling the growth of this category.
Hence, owing to the above-mentioned factors, the market for drug-in-adhesive will experience increased demand, thus driving the overall transdermal drug delivery devices market during the forecast period.
Transdermal Drug Delivery Devices Market Segmentation
Transdermal Drug Delivery Devices Market By Type
- Drug-in-adhesive Patches
- Matrix Patches
- Reservoir Membrane Patches
- Microneedle Patches
Transdermal Drug Delivery Devices Market By Application
- Pain Management
- Central Nervous System Disorders
- Hormonal Applications
- Cardiovascular Disorders, and Others
Transdermal Drug Delivery Devices Market By End-User
- Hospitals
- Ambulatory Surgical Centers, and Others
Transdermal Drug Delivery Devices Market by Geography
- North America Transdermal Drug Delivery Devices Market
- United States Transdermal Drug Delivery Devices Market
- Canada Transdermal Drug Delivery Devices Market
- Mexico Transdermal Drug Delivery Devices Market
- Europe Transdermal Drug Delivery Devices Market
- France Transdermal Drug Delivery Devices Market
- Germany Transdermal Drug Delivery Devices Market
- United Kingdom Transdermal Drug Delivery Devices Market
- Italy Transdermal Drug Delivery Devices Market
- Spain Transdermal Drug Delivery Devices Market
- Russia Transdermal Drug Delivery Devices Market
- Rest of Europe
- Asia-Pacific Transdermal Drug Delivery Devices Market
- China Transdermal Drug Delivery Devices Market
- Japan Transdermal Drug Delivery Devices Market
- India Transdermal Drug Delivery Devices Market
- Australia Transdermal Drug Delivery Devices Market
- South Korea Transdermal Drug Delivery Devices Market
- Rest of Asia Pacific
- Rest of the World (RoW)
- Middle East Transdermal Drug Delivery Devices Market
- Africa Transdermal Drug Delivery Devices Market
- South America Transdermal Drug Delivery Devices Market
Transdermal Drug Delivery Devices Regional Insights
North America is expected to dominate the overall transdermal drug delivery devices market:
Among all regions, North America Transdermal Drug Delivery Devices market is estimated to hold the largest share of 45.39% in the global transdermal drug delivery devices market in 2024, growing at a CAGR of 5.91% during the forecast period from 2025 to 2032. This can be attributed to the growing prevalence of targeted diseases such as chronic pain, central nervous system disorders, and cardiovascular diseases in the region, new product launches, and the increased focus on research and development activities among other factors that are driving the overall growth of the transdermal drug delivery devices market over the forecast period.
According to recent data from the Centers for Disease Control and Prevention (2024), approximately 4.9% of adults were diagnosed with coronary heart disease in 2022. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke.
Additionally, as per the recent data provided by the Alzheimer’s Association, in 2024, approximately 6.9 million Americans age 65 and older are living with Alzheimer's. Furthermore, as per the recent data provided by the Parkinson’s Foundation (2022), nearly 90,000 people are diagnosed with Parkinson’s disease in the U.S. each year and approximately one million people in the U.S. are living with Parkinson's disease (PD). This number is expected to rise to 1.2 million by 2030. Thus, the rising prevalence of these diseases, coupled with the demand for patient-friendly solutions that improve adherence and reduce systemic side effects, is accelerating the adoption of transdermal technologies.
Furthermore, the increasing number of product development activities in the region is further going to accelerate the growth of the spinal non-fusion devices market. For instance, in February 2024, LTS LOHMANN Therapie-Systeme AG announced the launch of the UDENYCA® on-body injector (OBI) through its Sorrel™ platform. UDENYCA® (pegfilgrastim-cbqv) aims to reduce infection risks post-chemotherapy. The FDA approved the device in December 2023, enhancing patient convenience and drug administration at home.
Thus, the above-mentioned factors are expected to escalate the Transdermal Drug Delivery Devices market in the region.
Transdermal Drug Delivery Devices Companies:
Some of the key Transdermal Drug Delivery Devices companies operating in the transdermal drug delivery devices market include:
- Novartis
- Viatris Inc.
- UCB SA
- Hisamitsu Pharmaceutical
- Boehringer Ingelheim
- Johnson & Johnson Services Inc.
- Purdue Pharma
- Bayer AG
- Haleon Group of Companies
- Ingenus Pharmaceuticals
- Luye Pharma Group
- Cumberland Pharmaceuticals Inc.
- Sanofi
- Sparsha Pharma International Pvt Ltd.
- Cipla
- Others
Recent Developmental Activities in the Transdermal Drug Delivery Devices Market:
- In July 2024, Kindeva Drug Delivery’s Woodbury, MN facility was FDA-inspected and classified. The facility now supports clients with integrated and stand-alone analytical services for pharmaceutical, biopharmaceutical, and medical device sectors.
- In March 2024, PassPort Technologies, Inc., a San Diego-based clinical-stage company, reported positive interim results from its Phase 1 trial of Zolmitriptan PassPort®, using a proprietary transdermal microporation system for acute migraine treatment. Zolmitriptan, an FDA-approved migraine medication, is tested for efficacy via this new delivery system.
Key Transdermal Drug Delivery Devices Highlights Summary (2022–2025)
| Category | Highlights (2022–2025) |
|---|---|
| Product Launches | - Corium launched Adlarity, a once-weekly donepezil patch for Alzheimer’s in 2022.- Novartis introduced a new transdermal patch for chronic pain in 2023.- Daewoong (South Korea) launched the microneedle platform CLOPAM in 2024. |
| Regulatory Approvals | - Zydus Lifesciences secured FDA approval for a generic scopolamine patch in 2024.- Sino Biopharmaceutical achieved NMPA approval (China) for its rivastigmine patch in 2024, the first domestically produced patch of its kind. |
| Partnerships | - Nutriband teamed up with Kindeva to develop an abuse-deterrent fentanyl patch via the FDA’s 505(b)(2) pathway in 2024.- Academic and cross-industry ventures are increasing in areas like AI-based patch development, biologics, psychedelics, and smart sensor integration. |
| Acquisitions | - DifGen acquired Aveva Drug Delivery Services in 2023, establishing its first U.S. production footprint.- Johnson & Johnson acquired a transdermal patch maker in 2022 to strengthen its delivery portfolio. |
| Company Strategy | - Kindeva expanded its analytical services in transdermal development with a new 32,000 sq ft lab in 2024.- Satio secured $3.5M in 2023 to advance a home-use microneedle-based delivery device. |
| Setbacks | - AbbVie discontinued its Androderm testosterone patch in 2023.- The FDA issued a warning in 2025 for the scopolamine patch due to heat-related overdose risks; label updates are in place.- Technical challenges persist—many patches struggle to deliver consistent doses or meaningful systemic absorption. |
| Emerging Technology | - Anodyne Nanotech’s HeroPatchT™ showed >50% bioavailability in preclinical semaglutide (GLP-1) patch studies, with clinical trials beginning in 2025.- Long-acting Guanfacine patch (3-day release) and insulin patch technologies are under development.- Advanced carriers like invasomes and transfersomes are being adopted to enhance skin penetration.- Smart insulin patches (glucose-responsive microneedle systems) are progressing, with multiple players moving toward clinical trials. |
Impact Analysis
AI Advancement in Transdermal Drug Delivery Devices
- AI-driven drug–skin interaction modeling - helps predict how different molecules penetrate skin layers, optimizing candidate selection for transdermal delivery.
- Formulation optimization - machine learning algorithms analyze huge datasets of excipients, enhancers, and polymers to design more effective and stable patch formulations.
- Personalized therapy - AI integrates patient data (age, skin type, genetics, health conditions) to recommend dosage and patch type for tailored treatment.
- Smart patches with AI sensors - wearable patches embedded with biosensors track vitals (glucose, temperature, hydration) and use AI to adjust or signal dosage in real time.
- Predictive analytics for clinical trials - AI models forecast efficacy, adherence, and safety outcomes, reducing trial costs and timelines.
- Manufacturing automation - AI enhances quality control by detecting micro-defects in microneedles, adhesive films, or drug layering during production.
- Digital twin technology - virtual simulations of patients’ skin and metabolism predict patch performance before physical testing.
- Adherence monitoring - AI-enabled apps and connected devices analyze patch usage patterns, alerting caregivers or physicians to non-compliance.
- Integration with big data & IoT - AI combines wearable sensor data with electronic health records for long-term disease management through patches.
- Drug repurposing insights - AI identifies existing molecules suitable for transdermal delivery, accelerating innovation pipelines.
Tariff Inclusion in Transdermal Drug Delivery Devices
The imposition of import tariffs on medical devices and components has significantly impacted the Transdermal Drug Delivery sector. These tariffs have led to increased costs, supply chain disruptions, and strategic shifts in manufacturing and sourcing. Understanding and navigating these changes is crucial for stakeholders aiming to maintain competitiveness and ensure uninterrupted patient care.
How This Analysis Helps Clients
- Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
- Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
- Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
- Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.
Startup Funding & Investment Trends in Transdermal Drug Delivery Devices
| Company / Startup | Total Funding / Grant | Main Products / Focus | Stage of Development | Core Technology / Platform |
|---|---|---|---|---|
| Vaxess Technologies | ~$27M Series B (2022); $12M (2024); $9M (2025) | Vaccine and therapeutic skin patches (e.g., flu, GLP-1) | Clinical trials (Phase 1+); advancing GLP-1 delivery studies | Microarray patch (MIMIX platform) |
| Satio, Inc. | $3.5M ARPA-H SBIR contract (2023) | SatioRx™, a remotely controllable microneedle patch for drugs and vaccines | Preclinical/device development | Disposable microneedle patch with remote dosing control |
| Transdermal Diagnostics | £1.1M pre-seed; £0.8M SBRI Healthcare grant (2025) | Needle-free continuous glucose monitoring patches | Early development / preclinical | Skin-wearable disposable patch for non-invasive glucose extraction |
| Anodyne Nanotech | ~$4.2M seed funding (2021); further $9.5M raised as of 2025 | Transdermal delivery of macromolecules and small molecules via porous microneedles | Early development / preclinical | Patent-pending porous microneedle platform |
| Micron Biomedical, Inc. | $23.6M for manufacturing scale-up (2023) | Needle-free vaccine administration patches | Scaling toward commercial manufacturing | Dissolvable microarray patches |
| Vaxxas Pty Ltd | ~$23M Series A (2022) | Intradermal vaccination patches (Nanopatch™) | Preclinical / scaling | Microprojection-based needle-free patch for vaccines |
Key Takeaways From the Transdermal Drug Delivery Devices Market Report Study
- Transdermal Drug Delivery Devices Market size analysis for current transdermal drug delivery devices size (2024), and market forecast for 8 years (2025 to 2032)
- Top key Transdermal Drug Delivery Devices product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
- Key Transdermal Drug Delivery Devices companies dominating the transdermal drug delivery devices market.
- Various opportunities available for the other competitors in the transdermal drug delivery devices market space.
- What are the top-performing segments in 2024? How these segments will perform in 2032?
- Which are the top-performing regions and countries in the current transdermal drug delivery devices market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for transdermal drug delivery devices market growth in the coming future?
Target Audience Who Can be Benefited From This Transdermal Drug Delivery Devices Market Report Study
- Transdermal drug delivery devices product providers
- Research organizations and consulting companies
- Transdermal Drug Delivery Devices -related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in transdermal drug delivery devices
- Various end-users who want to know more about the transdermal drug delivery devices market and the latest technological developments in the transdermal drug delivery devices market.
Get detailed insights @ DelveInsight Blogs
